A Phase 1, Multicenter, Open-Label, Dose Escalation Study of ASP9853 in Combination With Either Docetaxel or Paclitaxel in Subjects With Advanced Non-hematologic Malignancies

Trial Profile

A Phase 1, Multicenter, Open-Label, Dose Escalation Study of ASP9853 in Combination With Either Docetaxel or Paclitaxel in Subjects With Advanced Non-hematologic Malignancies

Discontinued
Phase of Trial: Phase I

Latest Information Update: 04 Aug 2014

At a glance

  • Drugs ASP 9853 (Primary) ; Docetaxel; Paclitaxel
  • Indications Cancer
  • Focus Adverse reactions
  • Sponsors Astellas Pharma
  • Most Recent Events

    • 01 Jul 2014 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 09 Apr 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 06 Nov 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top